Salicylamide (2-Hydroxybenzamide)

Salicylamide is an inhibitor of microsomal UDP-glucuronosyltransferase. Salicylamide is an analgesic and anti-pyretic agent.

Treatment with salicylamides leads to the bacterial growth inhibition which correlates with the level of inhibition of sulfate reduction[1].

Salicylamide administration decreases the levels of radiosulfate in maternal serum and placenta, and impaires the incorporation of radiosulfate into fetal skeletal GAGs. Salicylamide administration results in a decrease in the calcium content of fetal limb bones, but has no significant effect on maternal serum calcium[2]. Salicylamide administration decreases radiosulfate uptake by maternal serum and liver, fetus and placenta--effects being dose-dependent. Differences in radiosulfate uptake by the fetus and placenta over time, induced by salicylamide, are also significant independently of maternal serum levels of radiosulfate[3].

[1]. Kushkevych I, et al. Activity of selected salicylamides against intestinal sulfate-reducing bacteria. Neuro Endocrinol Lett. 2015;36 Suppl 1:106-13. [2]. Halstead PK, et al. Effect of salicylamide on skeletal glycosaminoglycan sulfation and calcification in fetal rat limbs. Drug Nutr Interact. 1981;1(1):75-86. [3]. Knight E, et al. Effect of salicylamide on the placental transfer and fetal tissue distribution of sodium-35S-sulfate in the rat. J Nutr. 1978 Feb;108(2):216-25.